Xenitra Highlights Pharmaceutical and Web3 Growth Plans After September-Quarter Sales
XEN: $0.002 +0.00% · MC: $14M
Xenitra’s November investor presentation outlines plans to expand its pharmaceutical and Web3 commerce businesses, following September-quarter pharmaceutical sales of approximately $864,000 and more than $2 million in Web3 sales since April, as reported in its recent quarterly update. The presentation describes pharmaceutical margin potential of 20% to 40% and Web3 margins of 40% to 90%; these are stated profiles, not reported realised margins.

Comments